The Wuxi base of Norroy is scheduled to be operational by 2023, encompassing a total construction area of approximately 3000 square meters. At present, the core technology platform has been established, which integrates the Linker technology for nuclear drugs, high-throughput screening and clinical transformation, and quantitative pharmacology of tumor drugs. At present, the original research and production of several innovative radioactive drugs and nuclear drug equipment are being carried out. The current operational covers 18F, 68Ga, 177Lu, 225Ac, a variety of species. The Wuxi base of Norroy is constructed according to the Chinese GMP standard, and has obtained the radiation safety license.